企业档案
会员类型：标准版
已获得阿仪网信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
阿仪网标准版会员：8年
工商认证 【已认证】
最后认证时间：无需年检
注册号：**** 【已认证】
法人代表：谭春** 【已认证】
参观次数：2676310
技术文章
文献引用产品：人外周血单个核细胞PBMC
点击次数：716 发布时间：2026/5/12 14:39:28
文章标题：Tranｓcriptional Activation of SBNO2 by KDM1A Drives Immune Escape in Lung Cancer
作者列表：Deguang Pan, Chong Zhang
影响因子：2.6
期刊：Advanced Biology
发表时间：2026-3-24
DOI:10.1002/adbi.202500639
文献主题：ABSTRACT
KDM1A is a crucial epigenetic modulator in tumor immune escape. Nevertheless, its precise regulatory function within the immune microenvironment of lung cancer needs investigation. Using TCGA data, we analyzed KDM1A and SBNO2 expression, clinical correlation, and immune infiltration. Functional assays included co-culture of lung cancer cells with CD8+ T cells, flow cytometry, Transwell migration, ChIP, and luciferase reporter assays. qPCR measured gene expression. KDM1A and SBNO2 were notably upregulated in lung cancer tissues, which correlated with poor patient prognosis and reduced CD8+ T cell infiltration. Functional experiments demonstrated that knockdown of KDM1A enhanced T cell proliferation, chemotaxis, and cytokine production. Mechanistically, KDM1A acted as a tranｓcription regulator binding to the SBNO2 promoter and positively regulated its mRNA expression in lung cancer cells. Importantly, rescue experiments confirmed that silencing SBNO2 expression abolished the pro-tumor immune escape effects induced by KDM1A overexpression. This study unveils a novel mechanism whereby KDM1A drives immune escape in lung cancer by tranｓcriptionally activating SBNO2, which subsequently suppresses the anti-tumor role of CD8+ T cells. These findings lend strong support to targeting the KDM1A-SBNO2 axis as a promising immunotherapeutic approach for lung cancer.
原创作者：上海雅吉生物科技有限公司
